Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

January 31, 2010

Conditions
Chronic Pain
Interventions
DRUG

Fentanyl Buccal Tablet

"FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.~The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).~For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician."

DRUG

Immediate release oxycodone

"Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.~The maximum single dose would be 60 mg (4 capsules)."

Trial Locations (50)

11516

Five Towns Neuroscience Research, Cedarhurst

14221

Upstate Clinical Research Associates, Williamsville

16602

Allegheny Pain Management, Altoona

19046

The Clinical Trial Center, LLC, Jenkintown

19139

CRI Worldwide, Philadelphia

19146

University of Pennsylvania, Philadelphia

19611

Clinical Research Center, West Reading

21045

Columbia Medical Practice, Columbia

21208

MidAtlantic Pain Medicine Center, Pikesville

29303

South Carolina Pharmaceutical Research, Spartanburg

29406

Trident Institute of Medical Research, LLC, North Charleston

29615

Greenville Pharmaceutical Research, Greenville

30060

Taylor Research, Marietta

30066

Drug Studies America, Marietta

30265

Georgia Pain Care, Newnan

31406

South Coast Medical Group, Savannah

32446

Emerald Coast Research Group Inc, Marianna

32806

Compass Research, LLC, Orlando

33324

Gold Coast Research, Plantation

33484

Delray Research Associates, Delray Beach

33603

Clinical Research of West Florida, Tampa

33701

Suncoast Neuroscience Associates, St. Petersburg

34238

Sarasota Pain Medicine Research, Sarasota

35215

Parkway Medical Center, Birmingham

36608

Horizon Research Group, Inc, Mobile

39202

CRC of Jackson, Jackson

40503

The Pain Treatment Center of the Bluegrass, Lexington

43551

Clinical Research Source Inc, Perrysburg

45267

University of Cincinnati Medical Center, Cincinnati

46250

Rehabilitation Associates of Indiana, Indianapolis

46514

Indiana Medical Research, Elkhart

46617

Indiana Pain & Spine Clinic, South Bend

48035

Michigan Neurology Associates PC, Clinton Township

60490

Suburban Clinical Research, Bolingbrook

61614

Knight Center for Integrated Health, Peoria

61701

Millennium Pain Center, Bloomington

63031

Healthcare Research, Florissant

66211

ICRI Inc., Overland Park

70708

Gulf Coast Research Associates, Inc, Baton Rouge

78215

Sun Research Institute, San Antonio

78759

Lovelace Scientific, Austin

84058

Aspen Clinical Research, Orem

89104

Clinical Research Center of Nevada, Las Vegas

90211

Robert Karns, MD a Medical Corporation, Beverly Hills

91710

Catalina Research Institute, LLC, Chino

92354

Loma Linda University Health, Loma Linda

92637

Pacific Coast Pain Management, Laguna Hills

95655

VA Northern California Health, Mather

97401

Pain Research of Oregon, Eugene

06611

New England Research Associates, Trumbull

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY

NCT00813488 - Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain | Biotech Hunter | Biotech Hunter